Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus POLYMOX.
NAFCILLIN SODIUM vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic